## Supplementary table 1. Characteristics of patients who received Atez/Bev as first-line systemic therapy (n=179)

|                                | Elderly patients (n=80) | Non-elderly patients (n=99) | p value |
|--------------------------------|-------------------------|-----------------------------|---------|
| Age* (years)                   | 81.0 (77.0–84.0)        | 68.0 (62.0–71.0)            | <0.001  |
| Sex (female/male)              | 26/54                   | 15/84                       | 0.007   |
| ECOG-PS (0/1/2/3/4)            | 58/17/4/1/0             | 85/9/4/0/1                  | 0.061   |
| Body mass index (kg/m²)        | 23.3 (21.1–25.3)        | 23.9 (21.3–26.8)            | 0.146   |
| Etiology of HCC (hepatitis B/C/non-B, non-C) | 7/34/39        | 21/28/50                   | 0.031   |
| Aspartate aminotransferase (IU/L) | 36 (27–57)             | 36 (26–58)                  | 0.979   |
| Alanine aminotransferase (IU/L) | 26 (17–38)             | 31 (20–43)                  | 0.081   |
| Albumin (g/dL)*                | 3.8 (3.5–4.1)           | 3.8 (3.4–4.1)               | 0.810   |
| Total bilirubin (mg/dL)*       | 0.7 (0.6–1.0)           | 0.8 (0.6–1.1)               | 0.417   |
| Platelet count (×10^3/m³)*     | 13.0 (10.7–17.3)        | 13.0 (9.8–20.3)             | 0.943   |
| Prothrombin time (%)*          | 88 (83–98)              | 89 (78–97)                  | 0.229   |
| Estimated glomerular filtration rate (mL/min/1.73 m²)* | 58.1 (47.2–72.2) | 72.5 (59.0–83.8) | <0.001 |
| α-fetoprotein (ng/mL)*         | 36.6 (7.2–542.0)        | 20.0 (5.7–293.8)            | 0.633   |
| Child-Pugh class (A/B/C)       | 76/4/0                  | 92/6/1                      | 1.000   |
| BCLC stage (A/B/C/D)           | 10/37/31/2              | 8/35/54/2                   | 0.190   |
| Follow-up duration* (months)   | 3.8 (2.0–6.7)           | 5.3 (3.1–8.2)               | 0.028   |
| Deaths                         | 7                       | 9                           | 1.000   |
| Causes of death (liver-related/ non–liver-related diseases) | 5/2 | 9/0 | 0.175 |

*Data are expressed as medians (interquartile range).
Atez/Bev, atezolizumab plus bevacizumab; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; HCC, hepatocellular carcinoma; BCLC, Barcelona Clinic Liver Cancer.